Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Berlin
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Kane Biotech Inc

+ Add to Watchlist

KA4:GR

0.036 EUR 0.004 10.00%

As of 13:36:13 ET on 05/04/2015.

Snapshot for Kane Biotech Inc (KA4)

Open: 0.037 Day's Range: 0.036 - 0.038 Volume: 0
Previous Close: 0.040 52wk Range: 0.020 - 0.072 1-Yr Rtn: -28.00%

Stock Chart for KA4

No chart data available.
  • KA4:GR 0.036
  • 1D
  • 1M
  • 1Y
0.040
Interactive KA4 Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for KA4

Current P/E Ratio (ttm) -
Estimated P/E(-) -
Relative P/E vs. DAX -
Earnings Per Share (ttm) -
Est. EPS -
Est. PEG Ratio -
Market Cap (M EUR) 3.86
Shares Outstanding (M) 107.27
30 Day Average Volume 400
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/20/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for KA4

  • Revenue
  • Net Income (M/CAD)
  • Profit Margin (%)

Company Profile & Key Executives for KA4

Kane Biotech Inc. is involved in the research and development of products to prevent and disperse bacterial biofilms. The Company's technology includes targets, methods, and processes involved in the formation of biofilms. Kane's technology has potential to improve the ability to prevent and/or destroy biofilms, in several medical and industrial applications.

Gordon FroehlichPresident/CEOMark MatthewsonChief Financial Officer
More Company Profile & Key Executives for KA4

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil